Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
Intervalo de año de publicación
1.
Proc Natl Acad Sci U S A ; 116(50): 25078-25086, 2019 12 10.
Artículo en Inglés | MEDLINE | ID: mdl-31767756

RESUMEN

The radical S-adenosylmethionine (SAM) enzyme NifB occupies a central and essential position in nitrogenase biogenesis. NifB catalyzes the formation of an [8Fe-9S-C] cluster, called NifB-co, which constitutes the core of the active-site cofactors for all 3 nitrogenase types. Here, we produce functional NifB in aerobically cultured Saccharomyces cerevisiae Combinatorial pathway design was employed to construct 62 strains in which transcription units driving different expression levels of mitochondria-targeted nif genes (nifUSXB and fdxN) were integrated into the chromosome. Two combinatorial libraries totaling 0.7 Mb were constructed: An expression library of 6 partial clusters, including nifUSX and fdxN, and a library consisting of 28 different nifB genes mined from the Structure-Function Linkage Database and expressed at different levels according to a factorial design. We show that coexpression in yeast of the nitrogenase maturation proteins NifU, NifS, and FdxN from Azotobacter vinelandii with NifB from the archaea Methanocaldococcus infernus or Methanothermobacter thermautotrophicus yields NifB proteins equipped with [Fe-S] clusters that, as purified, support in vitro formation of NifB-co. Proof of in vivo NifB-co formation was additionally obtained. NifX as purified from aerobically cultured S. cerevisiae coexpressing M. thermautotrophicus NifB with A. vinelandii NifU, NifS, and FdxN, and engineered yeast SAM synthase supported FeMo-co synthesis, indicative of NifX carrying in vivo-formed NifB-co. This study defines the minimal genetic determinants for the formation of the key precursor in the nitrogenase cofactor biosynthetic pathway in a eukaryotic organism.


Asunto(s)
Proteínas Bacterianas/metabolismo , Compuestos de Hierro/metabolismo , Saccharomyces cerevisiae/metabolismo , Azotobacter vinelandii/enzimología , Azotobacter vinelandii/genética , Proteínas Bacterianas/genética , Redes y Vías Metabólicas , Methanocaldococcus , Mitocondrias/metabolismo , Fijación del Nitrógeno/fisiología , Nitrogenasa/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Saccharomyces cerevisiae/genética , Biología Sintética
2.
J Am Chem Soc ; 140(12): 4302-4316, 2018 03 28.
Artículo en Inglés | MEDLINE | ID: mdl-29480720

RESUMEN

Centralized facilities for genetic engineering, or "biofoundries", offer the potential to design organisms to address emerging needs in medicine, agriculture, industry, and defense. The field has seen rapid advances in technology, but it is difficult to gauge current capabilities or identify gaps across projects. To this end, our foundry was assessed via a timed "pressure test", in which 3 months were given to build organisms to produce 10 molecules unknown to us in advance. By applying a diversity of new approaches, we produced the desired molecule or a closely related one for six out of 10 targets during the performance period and made advances toward production of the others as well. Specifically, we increased the titers of 1-hexadecanol, pyrrolnitrin, and pacidamycin D, found novel routes to the enediyne warhead underlying powerful antimicrobials, established a cell-free system for monoterpene production, produced an intermediate toward vincristine biosynthesis, and encoded 7802 individually retrievable pathways to 540 bisindoles in a DNA pool. Pathways to tetrahydrofuran and barbamide were designed and constructed, but toxicity or analytical tools inhibited further progress. In sum, we constructed 1.2 Mb DNA, built 215 strains spanning five species ( Saccharomyces cerevisiae, Escherichia coli, Streptomyces albidoflavus, Streptomyces coelicolor, and Streptomyces albovinaceus), established two cell-free systems, and performed 690 assays developed in-house for the molecules.


Asunto(s)
Escherichia coli/genética , Ingeniería Genética , Saccharomyces cerevisiae/genética , Streptomyces/genética , Aminoglicósidos/biosíntesis , Aminoglicósidos/química , Carbazoles/química , Carbazoles/metabolismo , Biología Computacional , Monoterpenos Ciclohexánicos , Enediinos/química , Escherichia coli/metabolismo , Alcoholes Grasos/química , Alcoholes Grasos/metabolismo , Furanos/química , Furanos/metabolismo , Lactonas/química , Lactonas/metabolismo , Estructura Molecular , Monoterpenos/química , Monoterpenos/metabolismo , Péptidos/química , Presión , Nucleósidos de Pirimidina/biosíntesis , Nucleósidos de Pirimidina/química , Pirrolnitrina/biosíntesis , Pirrolnitrina/química , Saccharomyces cerevisiae/metabolismo , Streptomyces/metabolismo , Tiazoles/química , Tiazoles/metabolismo , Factores de Tiempo , Vincristina/biosíntesis , Vincristina/química
3.
Nat Commun ; 12(1): 6343, 2021 11 03.
Artículo en Inglés | MEDLINE | ID: mdl-34732700

RESUMEN

Peptide secondary metabolites are common in nature and have diverse pharmacologically-relevant functions, from antibiotics to cross-kingdom signaling. Here, we present a method to design large libraries of modified peptides in Escherichia coli and screen them in vivo to identify those that bind to a single target-of-interest. Constrained peptide scaffolds were produced using modified enzymes gleaned from microbial RiPP (ribosomally synthesized and post-translationally modified peptide) pathways and diversified to build large libraries. The binding of a RiPP to a protein target leads to the intein-catalyzed release of an RNA polymerase σ factor, which drives the expression of selectable markers. As a proof-of-concept, a selection was performed for binding to the SARS-CoV-2 Spike receptor binding domain. A 1625 Da constrained peptide (AMK-1057) was found that binds with similar affinity (990 ± 5 nM) as an ACE2-derived peptide. This demonstrates a generalizable method to identify constrained peptides that adhere to a single protein target, as a step towards "molecular glues" for therapeutics and diagnostics.


Asunto(s)
Antivirales/química , Antivirales/farmacología , Péptidos/química , Péptidos/farmacología , SARS-CoV-2/efectos de los fármacos , COVID-19/virología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Cinética , Modelos Moleculares , Péptidos/genética , Unión Proteica , SARS-CoV-2/genética , SARS-CoV-2/fisiología , Glicoproteína de la Espiga del Coronavirus/química , Glicoproteína de la Espiga del Coronavirus/genética , Glicoproteína de la Espiga del Coronavirus/metabolismo , Tratamiento Farmacológico de COVID-19
4.
ACS Synth Biol ; 8(12): 2746-2755, 2019 12 20.
Artículo en Inglés | MEDLINE | ID: mdl-31750651

RESUMEN

Organism engineering requires the selection of an appropriate chassis, editing its genome, combining traits from different source species, and controlling genes with synthetic circuits. When a strain is needed for a new target objective, for example, to produce a chemical-of-need, the best strains, genes, techniques, software, and expertise may be distributed across laboratories. Here, we report a project where we were assigned phloroglucinol (PG) as a target, and then combined unique capabilities across the United States Army, Navy, and Air Force service laboratories with the shared goal of designing an organism to produce this molecule. In addition to the laboratory strain Escherichia coli, organisms were screened from soil and seawater. Putative PG-producing enzymes were mined from a strain bank of bacteria isolated from aircraft and fuel depots. The best enzyme was introduced into the ocean strain Marinobacter atlanticus CP1 with its genome edited to redirect carbon flux from natural fatty acid ester (FAE) production. PG production was also attempted in Bacillus subtilis and Clostridium acetobutylicum. A genetic circuit was constructed in E. coli that responds to PG accumulation, which was then ported to an in vitro paper-based system that could serve as a platform for future low-cost strain screening or for in-field sensing. Collectively, these efforts show how distributed biotechnology laboratories with domain-specific expertise can be marshalled to quickly provide a solution for a targeted organism engineering project, and highlights data and material sharing protocols needed to accelerate future efforts.


Asunto(s)
Ingeniería Metabólica , Nitrobencenos/metabolismo , Floroglucinol/metabolismo , Escherichia coli/metabolismo , Pruebas Genéticas , Floroglucinol/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA